99 related articles for article (PubMed ID: 26388189)
21. Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Roy UK; Stringer DE; Blohm-Mangone KA; Padilla-Torres JL; Guillen-R JM; Gerner EW
Nutr Cancer; 2006; 56(2):172-81. PubMed ID: 17474863
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of intestinal polyposis with reduced angiogenesis in ApcMin/+ mice due to decreases in c-Myc expression.
Yekkala K; Baudino TA
Mol Cancer Res; 2007 Dec; 5(12):1296-303. PubMed ID: 18171987
[TBL] [Abstract][Full Text] [Related]
23. Variations in the expression of the adenomatous polyposis coli (APC) tumor suppressor gene in human cancer cell lines of different tissue origin.
Dihlmann S; Amler LC; Schwab M; Wenzel A
Oncol Res; 1997; 9(3):119-27. PubMed ID: 9220497
[TBL] [Abstract][Full Text] [Related]
24. Apc mice: models, modifiers and mutants.
McCart AE; Vickaryous NK; Silver A
Pathol Res Pract; 2008; 204(7):479-90. PubMed ID: 18538487
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.
Hansen-Petrik MB; McEntee MF; Jull B; Shi H; Zemel MB; Whelan J
Cancer Res; 2002 Jan; 62(2):403-8. PubMed ID: 11809688
[TBL] [Abstract][Full Text] [Related]
26. Elevated Dnmt3a activity promotes polyposis in Apc(Min) mice by relaxing extracellular restraints on Wnt signaling.
Samuel MS; Suzuki H; Buchert M; Putoczki TL; Tebbutt NC; Lundgren-May T; Christou A; Inglese M; Toyota M; Heath JK; Ward RL; Waring PM; Ernst M
Gastroenterology; 2009 Sep; 137(3):902-13, 913.e1-11. PubMed ID: 19454286
[TBL] [Abstract][Full Text] [Related]
27. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
28. APC Asp1822Val and Gly2502Ser polymorphisms and risk of colorectal cancer and adenoma.
Tranah GJ; Giovannucci E; Ma J; Fuchs C; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):863-70. PubMed ID: 15824157
[TBL] [Abstract][Full Text] [Related]
29. Effect of targeting janus kinase 3 on the development of intestinal tumors in the adenomatous polyposis coli(min) mouse model of familial adenomatous polyposis.
Uckun FM; Erbeck D; Qazi S; Venkatachalam T; Tibbles HE; Vassilev A
Arzneimittelforschung; 2007; 57(6):320-9. PubMed ID: 17688077
[TBL] [Abstract][Full Text] [Related]
30. Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice.
Chiu CH; McEntee MF; Whelan J
Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):269-75. PubMed ID: 10883057
[TBL] [Abstract][Full Text] [Related]
31. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis.
Perkins S; Verschoyle RD; Hill K; Parveen I; Threadgill MD; Sharma RA; Williams ML; Steward WP; Gescher AJ
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):535-40. PubMed ID: 12050094
[TBL] [Abstract][Full Text] [Related]
32. Sex differences in the relationship of IL-6 signaling to cancer cachexia progression.
Hetzler KL; Hardee JP; Puppa MJ; Narsale AA; Sato S; Davis JM; Carson JA
Biochim Biophys Acta; 2015 May; 1852(5):816-25. PubMed ID: 25555992
[TBL] [Abstract][Full Text] [Related]
33. Chemoprevention of intestinal adenomatous polyposis by acetyl-11-keto-beta-boswellic acid in APC(Min/+) mice.
Liu HP; Gao ZH; Cui SX; Wang Y; Li BY; Lou HX; Qu XJ
Int J Cancer; 2013 Jun; 132(11):2667-81. PubMed ID: 23132636
[TBL] [Abstract][Full Text] [Related]
34. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
35. CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells.
Androutsopoulos VP; Ruparelia K; Arroo RR; Tsatsakis AM; Spandidos DA
Toxicology; 2009 Oct; 264(3):162-70. PubMed ID: 19666078
[TBL] [Abstract][Full Text] [Related]
36. Application of the Apc(Min/+) mouse model for studying inflammation-associated intestinal tumor.
Wang L; Zhang Q
Biomed Pharmacother; 2015 Apr; 71():216-21. PubMed ID: 25960239
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
38. Adenomatous polyposis coli determines sensitivity to the EGFR tyrosine kinase inhibitor gefitinib in colorectal cancer cells.
Zhang Y; Xiao Q; Zhang H; Sun X; Ge H; Liu X; Guan L; Sun M
Oncol Rep; 2014 Apr; 31(4):1811-7. PubMed ID: 24573033
[TBL] [Abstract][Full Text] [Related]
39. Raspberry pulp polysaccharides inhibit tumor growth via immunopotentiation and enhance docetaxel chemotherapy against malignant melanoma in vivo.
Yang YJ; Xu HM; Suo YR
Food Funct; 2015 Sep; 6(9):3022-34. PubMed ID: 26200777
[TBL] [Abstract][Full Text] [Related]
40. Adenomatous polyposis coli genotype-dependent toll-like receptor 4 activity in colon cancer.
Wen F; Liu Y; Wang W; Li M; Guo F; Sang Y; Qin Q; Wang Y; Li Q
Oncotarget; 2016 Feb; 7(7):7761-72. PubMed ID: 26760960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
